Literature DB >> 3500229

T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome.

A Raghavachar1, S Fleischer, N Frickhofen, H Heimpel, B Fleischer.   

Abstract

The idiopathic hypereosinophilic syndrome (HES) comprises a heterogeneous group of disorders with unknown pathogenesis characterized by persistent peripheral blood and bone marrow eosinophilia and eosinophilic infiltrates of multiple organs leading to severe organ dysfunction. In the present study, T lymphocyte clones were randomly established from the blood of a patient with HES and propagated in culture with mitogen and interleukin 2. Whereas 28 of 29 clones were able to stimulate myeloid colony formation when co-cultured with normal bone marrow cells in a double-layer micro-agar culture system, one third of these clones preferentially stimulated pure eosinophil colonies (up to 98% of all colonies). This pattern differed markedly (p less than 0.001) from the pattern of release of hemopoietic factors by 126 T cell clones established from four other individuals. Eosinophil colony stimulation was due to the release of a lineage-specific eosinophilic colony-stimulating factor (Eo-CSF) by these clones after appropriate stimulation. Production of Eo-CSF in vitro was inhibited by hydrocortisone or cyclosporin A. All Eo-CSF-producing clones had the T4+8-phenotype and were capable of producing in addition interleukin 2 and interferon-gamma. Southern blot analysis of the T cell receptor beta-chain rearrangement of the Eo-CSF-producing clones showed a different rearrangement pattern for each clone. These studies suggest a reactive T cell-mediated eosinophilia as the pathogenetic mechanism in this case of HES and, for the first time, point to a biologic relevance of a lymphokine-induced stimulation of hemopoiesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500229

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Determinants and regulating processes in bronchial hyperreactivity.

Authors:  H J Neijens
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 3.  Eosinophils: a review.

Authors:  B J McEwen
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

4.  New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.

Authors:  T Berki; M Dávid; B Bóné; H Losonczy; J Vass; P Németh
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 5.  Cytokines. 3. Cytokines in asthma.

Authors:  D S Robinson; S R Durham; A B Kay
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

Review 6.  Primary eosinophilic disorders: a concise review.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 7.  Regulation of colony-stimulating factor production by normal and leukemic human cells.

Authors:  T J Ernst; J D Griffin
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

8.  IL-5 in post-traumatic eosinophilic pleural effusion.

Authors:  L Schandené; B Namias; A Crusiaux; M Lybin; R Devos; T Velu; P Capel; R Bellens; M Goldman
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium.

Authors:  E Her; J Frazer; K F Austen; W F Owen
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

10.  Cyclosporin for hypereosinophilic syndrome.

Authors:  P Zabel; M Schlaak
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.